AR053065A1 - Compuestos azolicos neuroterapeuticos y composiciones farmaceuticas que los contienen - Google Patents

Compuestos azolicos neuroterapeuticos y composiciones farmaceuticas que los contienen

Info

Publication number
AR053065A1
AR053065A1 ARP060101598A ARP060101598A AR053065A1 AR 053065 A1 AR053065 A1 AR 053065A1 AR P060101598 A ARP060101598 A AR P060101598A AR P060101598 A ARP060101598 A AR P060101598A AR 053065 A1 AR053065 A1 AR 053065A1
Authority
AR
Argentina
Prior art keywords
substituted
group
alkyl
hydrogen
phenyl
Prior art date
Application number
ARP060101598A
Other languages
English (en)
Spanish (es)
Original Assignee
Sk Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37115369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR053065(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sk Corp filed Critical Sk Corp
Publication of AR053065A1 publication Critical patent/AR053065A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP060101598A 2005-04-22 2006-04-21 Compuestos azolicos neuroterapeuticos y composiciones farmaceuticas que los contienen AR053065A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67453005P 2005-04-22 2005-04-22

Publications (1)

Publication Number Publication Date
AR053065A1 true AR053065A1 (es) 2007-04-18

Family

ID=37115369

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101598A AR053065A1 (es) 2005-04-22 2006-04-21 Compuestos azolicos neuroterapeuticos y composiciones farmaceuticas que los contienen

Country Status (22)

Country Link
US (1) US7598279B2 (enExample)
EP (1) EP1879873B1 (enExample)
JP (1) JP5035238B2 (enExample)
KR (1) KR101286499B1 (enExample)
CN (1) CN101228138B (enExample)
AR (1) AR053065A1 (enExample)
AU (1) AU2006237798B2 (enExample)
BE (1) BE2021C524I2 (enExample)
BR (1) BRPI0607529B8 (enExample)
CA (1) CA2606258C (enExample)
DK (1) DK1879873T3 (enExample)
ES (1) ES2441765T3 (enExample)
FI (1) FIC20210018I1 (enExample)
MX (1) MX2007013197A (enExample)
MY (1) MY148589A (enExample)
NL (1) NL301106I2 (enExample)
PL (1) PL1879873T3 (enExample)
PT (1) PT1879873E (enExample)
RU (1) RU2418792C2 (enExample)
TW (1) TWI398249B (enExample)
WO (1) WO2006112685A1 (enExample)
ZA (1) ZA200709994B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
WO2008140197A1 (en) * 2007-05-14 2008-11-20 Sk Holdings Co., Ltd. Novel carbamoyloxy aryl alkan arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound
US8188301B2 (en) 2007-06-05 2012-05-29 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
CN102026988B (zh) * 2008-06-05 2013-07-03 爱思开生物制药株式会社 3-取代的丙胺化合物
WO2010150946A1 (en) * 2009-06-22 2010-12-29 Sk Holdings Co., Ltd. Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) * 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
KR101783633B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 섬유근육통 증후군의 치료 방법
EP2496228B1 (en) 2009-11-06 2014-01-15 SK Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
JP6232384B2 (ja) * 2012-01-06 2017-11-15 ノバルティス アーゲー 複素環式化合物およびその使用方法
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
TWI698415B (zh) * 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
ITUA20161941A1 (it) * 2016-03-23 2017-09-23 Univ Degli Studi Di Siena Uso di derivati dell’acido 2-amminotiofen-3- carbossilico per il trattamento delle dipendenze da cibo
KR102421006B1 (ko) * 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도
KR102489052B1 (ko) * 2016-05-19 2023-01-16 에스케이바이오팜 주식회사 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
KR102421013B1 (ko) * 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
MY199104A (en) * 2016-12-14 2023-10-13 Sk Biopharmaceuticals Co Ltd Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
PL3556349T3 (pl) * 2016-12-14 2022-04-11 Sk Biopharmaceuticals Co., Ltd. Preparat ciekły do podawania pozajelitowego zawierający związek karbaminianowy
ES2975254T3 (es) * 2016-12-14 2024-07-04 Sk Biopharmaceuticals Co Ltd Uso de compuestos de carbamato para la prevención, alivio o tratamiento del prurito
JP7090616B2 (ja) * 2016-12-14 2022-06-24 エスケー バイオファーマスティカルズ カンパニー リミテッド カルバメート化合物を含む口腔内崩壊錠
WO2018111006A1 (ko) 2016-12-14 2018-06-21 에스케이바이오팜 주식회사 탈수초성 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
JP7086076B2 (ja) * 2016-12-14 2022-06-17 エスケー バイオファーマスティカルズ カンパニー リミテッド 振戦又は振戦症候群の予防、軽減又は治療のためのカルバメート化合物の使用
KR102901908B1 (ko) * 2016-12-14 2025-12-17 에스케이바이오팜 주식회사 운동신경세포 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
KR102900173B1 (ko) * 2016-12-14 2025-12-12 에스케이바이오팜 주식회사 조현병, 강박장애 및 투렛증후군으로부터 선택되는 정신증 장애의 예방, 경감 또는 치료에 있어서의 카바메이트 화합물의 용도
JP7258901B2 (ja) * 2017-11-14 2023-04-17 エスケー バイオファーマスティカルズ カンパニー リミテッド 欠神発作又は欠神発作を示すてんかんの予防、軽減又は治療のためのカルバメート化合物の使用
WO2019098630A1 (ko) 2017-11-14 2019-05-23 에스케이바이오팜 주식회사 취약 x 증후군, 엔젤만 증후군 또는 렛 증후군을 포함하는 발달 장애의 경감 또는 치료를 위한 카바메이트 화합물의 용도
US11666554B2 (en) * 2017-11-14 2023-06-06 Sk Biopharmaceuticals Co., Ltd. Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease
US11406620B2 (en) 2017-11-14 2022-08-09 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing or treating diseases associated with increase in late sodium current
EP4545140A3 (en) 2017-11-14 2025-07-09 SK Biopharmaceuticals Co., Ltd. Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia
KR102900174B1 (ko) * 2017-11-14 2025-12-16 에스케이바이오팜 주식회사 근긴장증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
TWI826531B (zh) * 2018-09-21 2023-12-21 南韓商愛思開生物製藥股份有限公司 具有㗁二唑之化合物及包含該化合物之醫藥組合物
JP7408643B2 (ja) * 2018-09-21 2024-01-05 エスケー バイオファーマスティカルズ カンパニー リミテッド カルバメート化合物及びそれを含む製剤の急性ストレス障害又は心的外傷後ストレス障害の予防、軽減又は治療のための使用
CA3113052A1 (en) * 2018-09-21 2020-03-26 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for prevention, alleviation, or treatment of status epilepticus
TWI837197B (zh) * 2018-10-19 2024-04-01 南韓商愛思開生物製藥股份有限公司 胺基甲酸酯化合物於預防、緩解或治療糖尿病周邊神經病變或化療誘發的周邊神經病變的用途
US10611737B1 (en) 2019-10-24 2020-04-07 Sk Biopharmaceuticals Co., Ltd. Method for preparing aryl 2-tetrazol-2-yl ketone with improved selectivity
KR20220104746A (ko) * 2019-11-22 2022-07-26 에스케이바이오팜 주식회사 카바메이트 화합물을 포함하는 경구용 약제학적 조성물 및 그 제조방법
WO2022031099A1 (ko) * 2020-08-06 2022-02-10 에스케이바이오팜 주식회사 카바메이트 화합물을 포함하는 경구용 고형 제제 및 이의 제조방법
CN114317620B (zh) * 2020-09-29 2024-02-02 上海医药工业研究院 一种(r)-2-(2-氯苯基)环氧乙烷的生物制备方法
AR125970A1 (es) 2021-05-28 2023-08-30 Sk Biopharmaceuticals Co Ltd Formulaciones de suspensión acuosa para administración oral que comprenden un compuesto de carbamato
CN115974799B (zh) * 2021-10-14 2024-08-13 成都百裕制药股份有限公司 氨基甲酸酯取代的醇衍生物及其在医药上的应用
ES2931000B2 (es) * 2022-07-14 2023-07-07 Univ Madrid Complutense Proceso para la preparación de cenobamato
CN115716810B (zh) * 2022-11-15 2026-02-13 江苏艾立康医药科技有限公司 一种西诺氨酯的晶体形式及其制备方法
CN118239901A (zh) * 2023-03-15 2024-06-25 江苏恩华药业股份有限公司 一种氨基甲酸(r)-1-(2-氯苯基)-2-四唑-2-基乙酯的晶体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
DK181988A (da) 1988-03-30 1989-10-01 Dumex Ltd As Thiocarbamidsyreester til brug som terapeutikum samt praeparat til behandling af alkoholmisbrug
KR100221764B1 (ko) * 1991-08-22 1999-09-15 로즈 암스트롱, 크리스틴 에이. 트러트웨인 아미드 테트라졸 acat 억제제
KR100912521B1 (ko) * 2001-06-25 2009-08-18 에스케이 주식회사 2-헤테로시클릭-1,2-에탄디올의 카바메이트
US6770659B2 (en) * 2002-08-26 2004-08-03 Sk Corporation Benzoyl piperidine compounds
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds

Also Published As

Publication number Publication date
MY148589A (en) 2013-05-15
EP1879873A1 (en) 2008-01-23
AU2006237798B2 (en) 2012-07-12
JP2008538557A (ja) 2008-10-30
NL301106I2 (nl) 2021-08-03
BE2021C524I2 (enExample) 2025-12-10
CA2606258A1 (en) 2006-10-26
TW200722085A (en) 2007-06-16
RU2418792C2 (ru) 2011-05-20
BRPI0607529B1 (pt) 2021-05-18
EP1879873A4 (en) 2011-06-15
ZA200709994B (en) 2008-11-26
BRPI0607529B8 (pt) 2021-05-25
CN101228138A (zh) 2008-07-23
MX2007013197A (es) 2008-02-12
KR101286499B1 (ko) 2013-07-16
WO2006112685A1 (en) 2006-10-26
EP1879873B1 (en) 2013-10-09
NL301106I1 (nl) 2021-06-02
RU2007143073A (ru) 2009-05-27
CA2606258C (en) 2014-01-14
PT1879873E (pt) 2014-01-03
BRPI0607529A2 (pt) 2009-09-15
PL1879873T3 (pl) 2014-03-31
FIC20210018I1 (fi) 2021-06-14
AU2006237798A1 (en) 2006-10-26
US7598279B2 (en) 2009-10-06
KR20080005437A (ko) 2008-01-11
ES2441765T3 (es) 2014-02-06
JP5035238B2 (ja) 2012-09-26
TWI398249B (zh) 2013-06-11
CN101228138B (zh) 2012-11-21
DK1879873T3 (da) 2013-12-09
US20060258718A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
AR053065A1 (es) Compuestos azolicos neuroterapeuticos y composiciones farmaceuticas que los contienen
RU2388750C2 (ru) Ингибиторы фосфодиэстеразы 4, включая аналоги n-замещенного диариламина
AR066460A2 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
AR073136A1 (es) Compuestos de pirrol
AR069526A1 (es) Compuesto heterociclico que contiene nitrogeno y su uso
AR059184A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica
ATE507205T1 (de) Aromatische 1,4-di-carboxylamide und deren verwendung
AR060489A1 (es) Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol
AR055878A1 (es) Derivados de ciclopropanocarboxamida
DK2010531T3 (da) Spirocykliske cyklohexanderivater med smertestillende virkning
HRP20120963T1 (hr) PIRIDO-, PIRAZO- I PIRIMIDOPIRIMIDINSKI DERIVATI KAO mTOR INHIBITORI
PE20060626A1 (es) Aminas policiclicas sustituidas con arilo como antagonistas de mch1r
PT1289955E (pt) Piperidinas para utilizacao como antagonistas dos receptores da orexina
PE20091689A1 (es) DERIVADOS DE 4-AMINOCICLOHEXANO SUSTITUIDO CON ACTIVIDAD SOBRE RECEPTORES µ Y ORL-1
HRP20140687T1 (hr) Derivati benzofurana
HRP20050933A2 (en) Organic compounds
PE20091433A1 (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procedimientos para su preparacion 177
PE20091490A1 (es) Derivados sustituidos de indol
MXPA05010816A (es) Derivados de 4-(4- (heterociclilalcox}fenil)- 1-(heterociclil- carbonil) piperidina y compuestos relacionados como antagonistas de h3 de la histamina para el tratamiento de enfermedades neurologicas tales como alzheimer.
RU2014145819A (ru) Бициклическое соединение
ES2496592T3 (es) Proceso para la preparación de Imatinib y compuestos intermedios del mismo
BRPI1016232A2 (pt) Composto de carbinol, medicamento, regulador de lxr, composição farmacêutica, método para prevenir e/ou tratar doenças, e, uso do composto de carbinol
AR052915A1 (es) Derivados de pirrolidin y piperidin acetileno
AR066242A1 (es) Tia(di)azoles como antagonistas del recpetor de dopamina 2 de disociacion rapida
AR068373A1 (es) Derivados de n-fenilacetamida, inhibidores de la enzima soat-1, y composiciones farmaceuticas y cosmeticas que los contienen

Legal Events

Date Code Title Description
FG Grant, registration